drugset / Trial / NCT04969679
Additive Effect of Probiotics (Mutaflor®) in Patients With Ulcerative Colitis on 5-ASA Treatment.
RandomizedParallel-groupDouble-blindTreatment
Summary
E.coli Nissle 1917 (Mutaflor®) is equivalent to mesalazine in preventing disease relapse in ulcerative colitis. However, data on ability of E.coli Nissle 1917 (Mutaflor®) to induce remission compared with placebo is limited. Investigators aim to investigate the efficacy of E.coli Nissle 1917 (Mutaflor®) as an add-on treatment to 5-ASA in mild to moderate ulcerative colitis.
Timeline
- Start
- 2018-03-16
- Primary completion
- 2020-06-03
- Completion
- 2020-06-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | E. coli Nissle 1917 | Other / unclassified | 2 unknown | Oral |